2026年11月3日星期二
M
Rekod Semesta
Berita Pantas Global
Mitsubishi Heavy gears up to boost US gas turbine production— 日经 Nikkei AsiaNuclear reactors under construction rise to 79 globally on AI demand— 日经 Nikkei AsiaAI dubbing to help Japanese companies expand global outreach— 日经 Nikkei AsiaIndonesia GDP, US midterm elections, Hong Kong financial summit— 日经 Nikkei AsiaPakistan refineries report 1,860% jump in profit amid war windfall— 日经 Nikkei AsiaAfter US midterms, democracy will face test of ability to self-correct— 日经 Nikkei AsiaVietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei AsiaMitsubishi Heavy gears up to boost US gas turbine production— 日经 Nikkei AsiaNuclear reactors under construction rise to 79 globally on AI demand— 日经 Nikkei AsiaAI dubbing to help Japanese companies expand global outreach— 日经 Nikkei AsiaIndonesia GDP, US midterm elections, Hong Kong financial summit— 日经 Nikkei AsiaPakistan refineries report 1,860% jump in profit amid war windfall— 日经 Nikkei AsiaAfter US midterms, democracy will face test of ability to self-correct— 日经 Nikkei AsiaVietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei Asia

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

Sumber Nature 医学研究20 jam lalu
Ringkasan kandungan

Laman ini hanya menyediakan indeks tajuk dan ringkasan, kandungan penuh dan hak cipta adalah milik pihak penerbit asal, sila klik pautan asal untuk membaca.

Pergi ke artikel asal
Saluran berkaitan
Kesihatan
Kawasan berkaitan
Perspektif global
Bahasa teks asal
English
Nombor entri
health-00a74bed

Comments 0 comments

No comments yet. Be the first.

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials · Rekod Semesta